Group 1 - The core viewpoint of the article is that Baiyang Pharmaceutical has announced that its subsidiary, Baiyang Pharmaceutical, has received proposed selection qualifications for several drugs, which are expected to be implemented by the end of March 2026 [2] - The drugs that received proposed selection qualifications include: Nait (Nifedipine Controlled-Release Tablets), Naqi (Celecoxib Capsules), Naishu (Duloxetine Hydrochloride Enteric-Coated Capsules), and Naixin (Memantine Hydrochloride Sustained-Release Capsules) [2] - Currently, these drugs account for a small proportion of the company's revenue [2]